This inventor holds 3 USPTO granted patents and 8 published patent applications and 2 EPO patents. Top assignee: Elysium Health, Inc.. Active years: 2022-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2024
Title: The Innovative Contributions of Dan Alminana
Introduction
Dan Alminana is a notable inventor based in New York, NY (US). He has made significant contributions to the field of biochemistry, particularly in the development of nicotinamide riboside compounds. With a total of 3 patents to his name, Alminana's work has the potential to impact therapeutic methods in health and wellness.
Latest Patents
Alminana's latest patents include innovative formulations and methods related to nicotinamide riboside chloride. One of his patents focuses on the crystalline forms of nicotinamide riboside chloride, detailing methods of making these forms and their therapeutic applications. Another patent outlines efficient and scalable methods for synthesizing nicotinamide riboside from riboside triacetate, along with compositions and therapeutic methods that utilize this compound.
Career Highlights
Dan Alminana is currently associated with Elysium Health, Inc., a company dedicated to advancing health through innovative science. His work at Elysium Health emphasizes the importance of research and development in creating effective health solutions. Alminana's expertise in biochemistry and his innovative approach have positioned him as a key player in the field.
Collaborations
Alminana collaborates with talented individuals such as Mark Morris and Eric Marcotulli. These partnerships enhance the research and development efforts at Elysium Health, fostering an environment of innovation and creativity.
Conclusion
Dan Alminana's contributions to the field of biochemistry through his patents and work at Elysium Health highlight the importance of innovation in health sciences. His research on nicotinamide riboside compounds is paving the way for new therapeutic methods that could benefit many.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
